Hi Harvett, it could have a connection to the ESMO data presentation this weekend, as mentioned in Kazia September 2019 Investors Newsletter.
"Meanwhile, the Cantrixil phase I study has been progressing extremely well and is now close to completion, with completion expected in the first half of next year. New data will be reported at the upcoming ESMO conference in late September, and this should help to provide further insight into the potential efficacy of Cantrixil."
Regards.
- Forums
- ASX - By Stock
- KZA
- Cantrixil Study
Cantrixil Study, page-4
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)